BR112012017767A2 - marcador precoce de proteinúria em pacientes tratados com um tratamento anti-vegf - Google Patents
marcador precoce de proteinúria em pacientes tratados com um tratamento anti-vegfInfo
- Publication number
- BR112012017767A2 BR112012017767A2 BR112012017767A BR112012017767A BR112012017767A2 BR 112012017767 A2 BR112012017767 A2 BR 112012017767A2 BR 112012017767 A BR112012017767 A BR 112012017767A BR 112012017767 A BR112012017767 A BR 112012017767A BR 112012017767 A2 BR112012017767 A2 BR 112012017767A2
- Authority
- BR
- Brazil
- Prior art keywords
- vessel
- proteinuria
- pressure
- patients treated
- vegf treatment
- Prior art date
Links
- 239000003550 marker Substances 0.000 title 1
- 201000001474 proteinuria Diseases 0.000 title 1
- 238000000034 method Methods 0.000 abstract 3
- 239000012978 lignocellulosic material Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5091—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing the pathological state of an organism
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/94—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving narcotics or drugs or pharmaceuticals, neurotransmitters or associated receptors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/34—Genitourinary disorders
- G01N2800/347—Renal failures; Glomerular diseases; Tubulointerstitial diseases, e.g. nephritic syndrome, glomerulonephritis; Renovascular diseases, e.g. renal artery occlusion, nephropathy
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/50—Determining the risk of developing a disease
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Pharmacology & Pharmacy (AREA)
- Biochemistry (AREA)
- Epidemiology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Analytical Chemistry (AREA)
- Physics & Mathematics (AREA)
- Biotechnology (AREA)
- Cell Biology (AREA)
- Pathology (AREA)
- Microbiology (AREA)
- General Physics & Mathematics (AREA)
- Food Science & Technology (AREA)
- Organic Chemistry (AREA)
- Physiology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US28851409P | 2009-12-21 | 2009-12-21 | |
| PCT/US2010/061543 WO2011084791A2 (en) | 2009-12-21 | 2010-12-21 | Early marker of proteinuria in patients treated with an anti-vegf treatment |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112012017767A2 true BR112012017767A2 (pt) | 2019-09-24 |
Family
ID=44306097
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112012017767A BR112012017767A2 (pt) | 2009-12-21 | 2010-12-21 | marcador precoce de proteinúria em pacientes tratados com um tratamento anti-vegf |
Country Status (8)
| Country | Link |
|---|---|
| US (4) | US20130034861A1 (enExample) |
| EP (1) | EP2517014B1 (enExample) |
| JP (1) | JP5753541B2 (enExample) |
| AU (1) | AU2010339723B2 (enExample) |
| BR (1) | BR112012017767A2 (enExample) |
| CA (1) | CA2785273A1 (enExample) |
| ES (1) | ES2530866T3 (enExample) |
| WO (1) | WO2011084791A2 (enExample) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20090104649A1 (en) | 2007-06-11 | 2009-04-23 | Garovic Vesna D | Markers for preeclampsia |
| ES2530866T3 (es) | 2009-12-21 | 2015-03-06 | Mayo Foundation | Marcador temprano de proteinuria en pacientes tratados con un tratamiento anti-VEGF |
| EP2940471B1 (en) * | 2012-12-26 | 2019-09-18 | Hara, Masanori | Method for detecting podocytes in urine |
| WO2021055089A1 (en) * | 2019-09-20 | 2021-03-25 | The University Of North Carolina At Chapel Hill | Methods of identifying risk of bevacizumab-induced proteinuria and hypertension |
Family Cites Families (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9306053D0 (en) | 1993-03-24 | 1993-05-12 | Nycomed Pharma As | Method and assay |
| US6969591B2 (en) | 2000-10-27 | 2005-11-29 | Masanori Hara | Method for diagnosing nephropathy |
| US7713705B2 (en) | 2002-12-24 | 2010-05-11 | Biosite, Inc. | Markers for differential diagnosis and methods of use thereof |
| EP1481249A1 (en) | 2002-03-07 | 2004-12-01 | Cambridge University Technical Services Limited | Scd fingerprints |
| US20030198959A1 (en) * | 2002-03-28 | 2003-10-23 | Kurnit David M. | Methods and compositions for analysis of urine samples in the diagnosis and treatment of kidney diseases |
| GB0215509D0 (en) * | 2002-07-04 | 2002-08-14 | Novartis Ag | Marker genes |
| US7435419B2 (en) | 2002-07-19 | 2008-10-14 | Beth Israel Deaconess Medical Center | Methods of diagnosing and treating pre-eclampsia or eclampsia |
| JP2007532913A (ja) | 2004-04-16 | 2007-11-15 | ユニバーシティー オブ マサチューセッツ | 細胞内病原体の検出法および定量化法 |
| AU2005277350A1 (en) * | 2004-08-17 | 2006-03-02 | Arizona Board Of Regents On Behalf Of The University Of Arizona | Method of pre-selecting patients for anti-vegf, anti-hif-1 or anti-thioredoxin therapy |
| US7790463B2 (en) | 2006-02-02 | 2010-09-07 | Yale University | Methods of determining whether a pregnant woman is at risk of developing preeclampsia |
| US7820159B2 (en) * | 2006-10-31 | 2010-10-26 | Instiute of Virology of the Slovak Academy of Sciences | MN/CA IX and EGFR pathway inhibition |
| CA2672560A1 (en) * | 2006-12-15 | 2008-06-26 | Ruprecht-Karls-Universitaet Heidelberg | Methods for treating podocyte-related disorders |
| KR101722033B1 (ko) | 2007-05-21 | 2017-03-31 | 웨이크 포리스트 유니버시티 헬스 사이언시즈 | 소변으로부터의 전구 세포 및 이를 사용하는 방법 |
| US20090104649A1 (en) | 2007-06-11 | 2009-04-23 | Garovic Vesna D | Markers for preeclampsia |
| US20090068683A1 (en) | 2007-06-11 | 2009-03-12 | Mayo Foundation For Medical Education And Research | Markers for preeclampsia |
| CA2703154A1 (en) * | 2007-10-25 | 2009-04-30 | Philogene, Inc. | Antibodies specific to pro-angiogenic isoforms of vascular endothelial growth factor (vegf) |
| WO2010065968A1 (en) | 2008-12-05 | 2010-06-10 | Myriad Genetics, Inc. | Cancer detection markers |
| EP2442106B1 (en) | 2009-06-10 | 2015-08-19 | Masanori Hara | Method for test on diabetic nephropathy |
| ES2530866T3 (es) | 2009-12-21 | 2015-03-06 | Mayo Foundation | Marcador temprano de proteinuria en pacientes tratados con un tratamiento anti-VEGF |
| WO2011143499A1 (en) | 2010-05-12 | 2011-11-17 | Tengion, Inc. | Bioactive renal cells |
| CA2875137C (en) | 2012-06-01 | 2021-06-08 | Mayo Foundation For Medical Education And Research | High-throughput early detection and point-of-care early detection of pregnant women susceptible to developing preeclampsia |
| CN104736724A (zh) | 2012-10-05 | 2015-06-24 | 日立化成株式会社 | 尿液外泌小体mRNA和使用其检测糖尿病型肾病的方法 |
| WO2015080838A1 (en) | 2013-11-27 | 2015-06-04 | Mayo Foundation For Medical Education And Research | Detecting podocyte injury in diabetic nephropathy and glomerulonephritis |
-
2010
- 2010-12-21 ES ES10842718T patent/ES2530866T3/es active Active
- 2010-12-21 BR BR112012017767A patent/BR112012017767A2/pt not_active IP Right Cessation
- 2010-12-21 EP EP10842718.8A patent/EP2517014B1/en not_active Not-in-force
- 2010-12-21 JP JP2012546149A patent/JP5753541B2/ja not_active Expired - Fee Related
- 2010-12-21 WO PCT/US2010/061543 patent/WO2011084791A2/en not_active Ceased
- 2010-12-21 CA CA2785273A patent/CA2785273A1/en not_active Abandoned
- 2010-12-21 US US13/518,358 patent/US20130034861A1/en not_active Abandoned
- 2010-12-21 AU AU2010339723A patent/AU2010339723B2/en not_active Ceased
-
2013
- 2013-05-20 US US13/898,124 patent/US9213038B2/en active Active
-
2015
- 2015-11-09 US US14/935,784 patent/US9765137B2/en active Active
-
2017
- 2017-09-13 US US15/703,676 patent/US10336822B2/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| WO2011084791A3 (en) | 2011-11-24 |
| US20180002416A1 (en) | 2018-01-04 |
| ES2530866T3 (es) | 2015-03-06 |
| EP2517014A4 (en) | 2013-07-17 |
| US10336822B2 (en) | 2019-07-02 |
| CA2785273A1 (en) | 2011-07-14 |
| JP2013515268A (ja) | 2013-05-02 |
| WO2011084791A2 (en) | 2011-07-14 |
| US20130296397A1 (en) | 2013-11-07 |
| US20130034861A1 (en) | 2013-02-07 |
| AU2010339723A1 (en) | 2012-08-09 |
| US9213038B2 (en) | 2015-12-15 |
| AU2010339723B2 (en) | 2014-11-06 |
| US20160060333A1 (en) | 2016-03-03 |
| US9765137B2 (en) | 2017-09-19 |
| JP5753541B2 (ja) | 2015-07-22 |
| EP2517014B1 (en) | 2014-11-19 |
| EP2517014A2 (en) | 2012-10-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112012017763A2 (pt) | método e processo para descarga seca em um reator de pré-tratamento pressurizado. | |
| BR112013013136A2 (pt) | processo de produção de biogás | |
| BR112013004700A2 (pt) | método para prevenir ou tratar doenças ou distúrbios cardiovasculares | |
| WO2011031435A3 (en) | Reducing hydrogen consumption in hydrotreating of biocomponent feeds | |
| BR112013008472A2 (pt) | hidrólise ensimática de material lignocelulósico na presença de sulfito, ditionito e/ou ditiotreitol | |
| BRPI0517337A (pt) | método e aparelho para tratar continuaente um material de biomassa | |
| WO2010039532A3 (en) | Disabling cache portions during low voltage operations | |
| BR112012018422A2 (pt) | processo para produção de biogás com pré-tratamento enzimático. | |
| MX2012006759A (es) | Tejido adiposo descelularizado. | |
| BRPI0911176B8 (pt) | método de tratar uma composição de célula vermelha sanguínea, composição de célula vermelha sanguínea, e método de reduzir a desidratação em uma composição de célula vermelha sanguínea | |
| UY30967A1 (es) | Proceso para el control de "pitch" | |
| MX2016001909A (es) | Metodo para aislar lignina de un biomasa y productos proporcionados de la misma. | |
| BR112015019997A2 (pt) | Métodos de sacarificar e fermentar um material celulósico | |
| BRPI1015952B8 (pt) | Método de introdução de uma nuclease sequência-específica (ssn) em uma célula vegetal | |
| BR112013027307A2 (pt) | método para tratar uma matriz de tecido; matriz de tecido acelular | |
| AR076541A1 (es) | Mutantes de fgf21 y usos del mismo | |
| BR112015004990A2 (pt) | método e aparelho para resfriamento de biomassa pré-tratada antes da mistura com enzimas | |
| BR112012017767A2 (pt) | marcador precoce de proteinúria em pacientes tratados com um tratamento anti-vegf | |
| PH12015502111B1 (en) | Stabilized chlorine dioxide to preserve carbohydrate feedstocks | |
| MX365464B (es) | Prodecimiento para preparar inhibidores de la glucosilceramida sintasa. | |
| BR112018010451A2 (pt) | processo para reduzir o consumo total de energia na produção de uma dispersão de nanocelulose, dispersão de nanocelulose, hidrogel e organo-gel | |
| BR112018016151A2 (pt) | método de produção de ácidos graxos | |
| BR112012003861A2 (pt) | método e disposição para adicionar licores de tratamento a uma matéria-prima celulósica em um processo contínuo utilizando vasos de fluxo descendente | |
| BR112018006278A2 (pt) | proteína lisossômica modificada e produção da mesma | |
| CN203291013U (zh) | 一种防断式骨钉 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] | ||
| B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2543 DE 01-10-2019 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013. |